Lilly’s offering is expected to surpass Novo’s Wegovy in the space, and, according to a report this week from GlobalData, it ...

The approval is expected to be extended following the anticipated final consent from the Israeli police department.

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Operational risks are also reduced due to a lesser need for human intervention in hazardous environments, which is a very ...

These digitalisation initiatives could provide long-term benefits to the oil and gas industry, says GlobalData. GlobalData’s ...

It’s become evident that a cloud-based IT portfolio brings organisations the greatest promise for providing the type of ...

KOLs interviewed by GlobalData stressed the lack of biologic therapies specifically targeting T2-low asthma.

In a release sent to Rigzone recently, GlobalData said the oil and gas industry has seen a dip in active jobs in 2024 but ...

AI-driven adaptive cardiac devices are revolutionizing heart disease treatment by enabling real-time monitoring and dynamic ...

GlobalData predicts five technology trends to watch in 2025. AI remains the most talked about trend with a focus on Agentic AI going forward.

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior efficacy and ...

Eli Lilly's Zepbound is challenging Wegovy in the obesity market, while U.S. health care costs are set to rise 9% in 2025, driven by specialty drugs and inflation.